# Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

> **NCT01104571** · PHASE3 · UNKNOWN · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 257 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** lapatinib ditosylate
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT01104571
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-04
- **Primary completion:** 2017-08-30
- **Final completion:** 2025-09
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2018-09-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01104571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01104571, "Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01104571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*